Nanosuspension technology: A review

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue SUPPL. 4, 2010, Pages 35-40

  Lakshmi, Prasanna ^a   Kumar, Giddam Ashwini ^a  

^a Bharat Institute of Technology   (India)

Author keywords

Dissolution; Nanosuspension; Saturation solubility; Solubility enhancement; Surfactant

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; APHIDICOLIN; ATORVASTATIN; ATOVAQUONE; BUDESONIDE; BUPRAQUONE; CARBAMAZEPINE; CELECOXIB; CLOFAZIMINE; CLORICROMEN; CYCLOSPORIN; DANAZOL; DICLOFENAC; FENOFIBRATE; FLUTICASONE; HYDROCORTISONE; IBUPROFEN; NANOCRYSTAL; NAPROXEN; NIMODIPINE; OLEANOLIC ACID; OMEPRAZOLE; ORGANIC SOLVENT; ORIDONIN; PACLITAXEL; PREDNISOLONE; SPIRONOLACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HYDROGEL; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MUCOADHESION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRECIPITATION; REVIEW; SHELF LIFE; SUPERCRITICAL FLUID; SUSPENSION; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 78649737917     PISSN: 09751491     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Elaine Merisko-Liversidge, Gary G. Liversidge, Eugene R. Cooper. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur.J.Pharm.Sci.2003; 18:113-120.
2. Dubey R. Impact of nanosuspension technology on drug discovery and development. Drug Deliv Technol 2006;6:65-67.
3. Amidon GL, Lennerna's H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-420.
4. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. Biopharmaceutics classification system: the scientific basis for biowaiver Extensions. Pharm Res 2002;19:921-925.
5. Lennerna's H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005;57:273-285.
6. Varshosaz J, Talari R, Mostafavi SA, Nokhodchi A. Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Technology 2008;187:222-230.
7. Pahala S, Joan MA, Samuel HY. Solubilization of rapamycin. Int J Pharm 2001;213: 25-29.
8. Abu Serajuddin TM. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews 2007;59:603-616.
9. Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm 2006;317:61-68.
10. Marazban S, Judith B, Xiaoxia C, Steve S, Robert O, Williams III, Keith PJ. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm 2002;243:17-31.
11. True LR, Ian BG, James EH, Kevin LF, Clindy AC, Chritoper JT. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly soluble drugs. Pharm Res 2004;2111:2048-2057.
12. Riaz M. Stability and uses of liposomes. Pak Pharm Sci 1995;82:69-79.
13. Floyd AG. Top ten considerations in the development of parenteral Emulsions. Pharm Sci Tech 1999;4:134-143
14. Nakano M. Places of emulsions in rug delivery. Adv Drug Deliv Rev 2000;45:1-4.
15. Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ. Applications of microemulsion based drug delivery system. Cur Dr del 2006;33:267-273.
16. Lawrence MJ, Rees GD. icroemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
17. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;501:47-60.
18. Hemant NJ, Ravindra WT, Martha D, Vaishali PS, Mohammed J, Mohinder SB, Sailesh AV, Abu Serajuddin TM. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture: Int J Pharm 2004;269:251-258.
19. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997;14:556-567.
20. Loftsson T, Brewster M. Pharmaceutical applications of cyclodextrins. J Pharm Sci 1996;85:1017-1025.
21. Marcela L, Mari'a M. De Bertorello, Marcela L. Solubilization of naphthoquinones by complexation with hydroxypropyl-b-cyclodextrin. Int J Pharm 1997;159:13-18.
22. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309-313.
23. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, M'uller RH, Ehlers S. Preparation of clofazamine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in Mycobacterium avium infection. J Antimicrob Chem 2000;45:77-83.
24. Jacobs C, Kayser O, M'uller RH. Production and characterization of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm 2001;214:3-7.
25. Debuign F, Cuisenaire J, Jeunieau L, Masereel B, Nagy JB. Synthesis of nimesulid nanoparticles in the microemulsion epikuron/isopropyl myristate/water/n-butanol or isopropanol. J Colloid Interface Sci 2001;243:90-101.
26. Trotta M, Gallarete M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release 2001;76:119-128.
27. Kayser O, Olbrich C, Yardley V, Kinderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003;254:73-75.
28. M'oschwitzer J, Achleitner G, Pomper H, M'uller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615-619.
29. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterisation of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm 2005;299:167-177.
30. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm 2005;31:319-329.
31. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions. a promising drug delivery strategy. J Pharm Pharmacol 2004;56:827-840.
32. Kesisoglou F, Panmai S, Wu. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59:631-644.
33. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006;62:3-16.
34. Rabinow B. Nanosuspensions in drug delivery. Nature 3 2004;785-793.
35. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-186.
36. Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-dilutable micro-emulsions. Int J Pharm 2003;254:235-242.
37. Zhang X, Xia Q, Gu N. Preparation of All-Trans Retinoic Acid Nanosuspensions Using a Modified Precipitation Method. Drug Development and Industrial Pharmacy 2006;32:857-863.
38. Liversidge GG, Cundy K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125 91-97.
39. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing. A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-120.
40. Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. 1999.
41. Jacobs C, Kayser O, Muller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000;196:161-164.
42. Anchalee AA, Pardeep KG. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm 2008;351:282-288.
43. Ruolan X, Weigen L, Jun L, Peiquan W, Rong X, Tingting C. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm 2008;350:338-343.
44. Muller RH, Jacobs C, Kayser O, Rathbone MJ, Hadgraft J, Roberts MS. Modified-Release Drug Delivery Technology. New york. Basel;2003. P. 135-149.
45. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs. Int J Pharm 1998;160:229-237.
46. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-186.
47. Francesco L, Chiara S, Guido E, Francesc M, Giaime M, Anna MF. Diclofenac nanosuspensions. Influence of preparation procedure and crystal form on drug dissolution behavior. Int J Pharm 2009;373:124-132.
48. Panchaxari D, Shashidhar K, Vinayak M, Anand G, Anandrao K. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. Ira J Pharm Res 2009;82:79-86.
49. Thote AJ, Gupta RB. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine: Nanotech. Biology Medicine 2005;1:85-90.
50. Chattophadhyay P, Gupta RP. Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. Int J Pharm 2001;228:19-31.
51. Sun Y, Mezian M, Pathak P, Qu L. Polymeric nanoparticles from rapid expansion of supercritical fluid solution. Chemistry 2005;11:1366-1373.
52. Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol Prog 2000;16:402-407.
53. Müller RH. Zetapotential und Partikelladung-Kurze Theorie, praktische MeBdurchfuhrung, Dateninterpretation. Wissenschaftliche Verlagsgesellschaft, Stuttgart. 1996.
54. Andrej D, Julijana K, Säsa B, Odon PS. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm 2009;376:204-212.
55. Lenhardt T, Vergnault G, Grenier P, Scherer D, Langguth P. Evaluation of Nanosuspensions for Absorption Enhancement of Poorly Soluble Drugs: In Vitro Transport Studies Across Intestinal Epithelial Monolayers. The AAPS Journal 2008; Vol. 10, No. 3.
56. Hanafy A, Spahn-Langguth HG. Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T, Langguth P. Pharmacokinetic evaluation of oral fenofibrate nanosuspension and SLN in comparison to conventional suspension of micronized drug. Advanced drug delivery reviews 2007;Volume 59 Issue 6:419-426.
57. Liversidge GC. Workshop on particulate drug delivery systems. Paper presented at the 23 International symposium of the controlled release bioactive maerial society. 1996.
58. Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanoic acid nanosuspension: preparation, in vitro characterization and enhanced hepato protective effect. J Pharm Pharmacol 2005;57:259-264.
59. SchbTer N, Krause K, Kayser O, Muller RH, Borner K, Hahn H, Liesenfeld O. Atovaquone nanosuspensions show excelent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother 2001;45:1771-9.
60. Sagar MA, Pradeep RV. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine: Nanotechnology, Biology, and Medicine 2009;5:90-95.
61. Hany SMA, Peter Y, Nicholas B. Preparation of hydrocortisone nanosuspension through a botom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009;375:107-113.
62. Rosario P, Claudio B, Piera F, Adriana M, Antonina P. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53-61.
63. Rosario P, Nadia R, Claudio B, Francesco M, Adriana M, Giovanni P. Preparation and Characterization of Eudragit Retard Nanosuspensions for the Ocular Delivery of Cloricromene. AAPS PharmSciTech 2006; 7 1.
64. Haiyan L, Xiumei Z, Lei G, Feifei F, Juying W, Xinbing W, Zongqin Y, Dianrui Z, Qiang Z. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharma 2009; 379:181-186.
65. Jacobs C, Kayder O, Muller RH. Nanosuspension as a new approach for the formulation of poorly soluble drug tarazepine. Int J Pharm 2000;196:161-4.
66. Po-Chang Chiang, Jason W. Alsup, Yurong Lai, Yiding Hu, Bruce R. Heyde, David Tung. Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery. Nanoscale Res Lett 2009;4:254-261.
67. Muller RH, Jacobs C. production and characterization of Budesonide nanosuspension for pulmonary administration. Pharm Res 2002;19:189-194.
68. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002;237:151-161.
69. Shim J, Kang HS, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Rel 2004;97:477-484.
70. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery. Effect of particle size and charge. Int J Pharm 2004; 275:13-7.
71. Yamaguchi Y, Nagasawa T, Nakamura N, Takenaga M, Mizoguchi M, Kawai SI, Mizushima Y, Igarashi R. Successful treatment of photo-damaged skin of nano-scale at RA particles using a novel transdermal delivery. J Control Rel 2005; 104:29-40.